Advances and challenges in geroscience research: An update
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Aging remains the most pervasive risk factor for a wide range of chronic diseases that afflict modern societies. In the United States alone, incidence of age-related diseases (e.g., cardiovascular disease, stroke, Alzheimer’s disease, vascular cognitive impairment and dementia, cancer, hypertension, type-2 diabetes, chronic obstructive pulmonary disease, and osteoarthritis) is on the rise, posing an unsustainable socioeconomic burden even for the most developed countries. Tackling each and every age-related disease alone is proving to be costly and ineffective. The emerging field of geroscience has posed itself as an interdisciplinary approach that aims to understand the relationship between the biology of aging and the pathophysiology of chronic age-related diseases. According to the geroscience concept, aging is the single major risk factor that underlies several age-related chronic diseases, and manipulation of cellular and systemic aging processes can delay the manifestation and/or severity of these age-related chronic pathologies. The goal of this endeavor is to achieve health improvements by preventing/delaying the pathogenesis of several age-related diseases simultaneously in the elderly population by targeting key cellular and molecular processes of aging instead of managing diseases of aging as they arise individually. In this review, we discuss recent advances in the field of geroscience, highlighting their implications for potential future therapeutic targets and the associated scientific challenges and opportunities that lay ahead.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 2×
“Advances in mTOR signaling There is growing evidence suggesting that inhibition of the evolutionarily conserved mammalian target of rapamycin (mTOR, also known as mechanistic target of rapamycin) pathway may have protective effects against aging (3, 22).”
BackgroundAn epigenetic biomarker of aging for lifespan and healthspan
Levine, M. E., Lu, A. T., Quach, A., Chen, B. H., Assimes, T. L., Bandinelli, S., Hou, L., Baccarelli, A. A., Stewart, J. D., Li, Y., et al. (2018) · Aging · doi:10.18632/aging.101414 · Cited by 3,675
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312 · cited 1×
“BBB disruption is another important factor, which plays a key role in increased neuroinflammation in the aging brain (58, 69, 73), likely contributing to the pathogenesis of Alzheimer’s disease and vascular cognitive impairment (56, 57).”
BackgroundSenolytics improve physical function and increase lifespan in old age
Xu, M., Pirtskhalava, T., Farr, J. N., Weigand, B. M., Palmer, A. K., Weivoda, M. M., Inman, C. L., Ogrodnik, M. B., Hachfeld, C. M., Fraser, D. G., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0092-9 · Cited by 2,287
Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
Chang, J., Wang, Y., Shao, L., Laberge, R.-M., Demaria, M., Campisi, J., Janakiraman, K., Sharpless, N. E., Ding, S., Feng, W., et al. (2016) · Nature Medicine · doi:10.1038/nm.4010 · Cited by 1,819 · cited 1×
“Recent studies have identified dasatinib plus quercetin (85), heat shock protein 90 (HSP90) inhibitors (18), fisetin (86), mouse double minute 2 homolog antagonists (82) and agents acting on oxidation resistance protein 1 (87), and B-cell lymphoma 2 (8) as a potential senolytic agents that could extend health span and…”
BackgroundJeon, O. H., Kim, C., Laberge, R.-M., Demaria, M., Rathod, S., Vasserot, A. P., Chung, J. W., Kim, D. H., Poon, Y., David, N., et al. (2017) · Nature Medicine · doi:10.1038/nm.4324 · Cited by 1,515 · cited 2×
“This knowledge will enable the development of novel treatments aimed at removing the senescent cellular burden to increase health span by delaying/preventing age-associated pathologies (26, 46).”
BackgroundSenescent intimal foam cells are deleterious at all stages of atherosclerosis
Childs, B. G., Baker, D. J., Wijshake, T., Conover, C. A., Campisi, J., & van Deursen, J. M. (2016) · Science · doi:10.1126/science.aaf6659 · Cited by 1,195
Zhu, Y., Tchkonia, T., Fuhrmann‐Stroissnigg, H., Dai, H. M., Ling, Y. Y., Stout, M. B., Pirtskhalava, T., Giorgadze, N., Johnson, K. O., Giles, C. B., et al. (2016) · Aging Cell · doi:10.1111/acel.12445 · Cited by 1,148 · cited 1×
“The concept has been increasingly accepted that by targeting fundamental aging processes, it may be possible to ameliorate a vast array of human diseases associated with old age and is destined to revolutionize the way we think about aging research (6, 28, 29, 43, 50, 84, 85, 88).”
BackgroundMetformin as a tool to target aging
Barzilai, N., Crandall, J. P., Kritchevsky, S. B., & Espeland, M. A. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.011 · Cited by 1,096 · cited 2×
“The concept has been increasingly accepted that by targeting fundamental aging processes, it may be possible to ameliorate a vast array of human diseases associated with old age and is destined to revolutionize the way we think about aging research (6, 28, 29, 43, 50, 84, 85, 88).”
BackgroundFisetin is a senotherapeutic that extends health and lifespan
Yousefzadeh, M. J., Zhu, Y., McGowan, S. J., Angelini, L., Fuhrmann-Stroissnigg, H., Xu, M., Ling, Y. Y., Melos, K. I., Pirtskhalava, T., Inman, C. L., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.015 · Cited by 1,032 · cited 1×
“Recent studies have identified dasatinib plus quercetin (85), heat shock protein 90 (HSP90) inhibitors (18), fisetin (86), mouse double minute 2 homolog antagonists (82) and agents acting on oxidation resistance protein 1 (87), and B-cell lymphoma 2 (8) as a potential senolytic agents that could extend health span and…”
BackgroundUngvari, Z., Tarantini, S., Donato, A. J., Galvan, V., & Csiszar, A. (2018) · Circulation Research · doi:10.1161/circresaha.118.311378 · Cited by 919
Self-citationRoos, C. M., Zhang, B., Palmer, A. K., Ogrodnik, M. B., Pirtskhalava, T., Thalji, N. M., Hagler, M., Jurk, D., Smith, L. A., Casaclang‐Verzosa, G., et al. (2016) · Aging Cell · doi:10.1111/acel.12458 · Cited by 738 · cited 1×
“The concept has been increasingly accepted that by targeting fundamental aging processes, it may be possible to ameliorate a vast array of human diseases associated with old age and is destined to revolutionize the way we think about aging research (6, 28, 29, 43, 50, 84, 85, 88).”
BackgroundIdentification of HSP90 inhibitors as a novel class of senolytics
Fuhrmann-Stroissnigg, H., Ling, Y. Y., Zhao, J., McGowan, S. J., Zhu, Y., Brooks, R. W., Grassi, D., Gregg, S. Q., Stripay, J. L., Dorronsoro, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00314-z · Cited by 701 · cited 1×
“Recent studies have identified dasatinib plus quercetin (85), heat shock protein 90 (HSP90) inhibitors (18), fisetin (86), mouse double minute 2 homolog antagonists (82) and agents acting on oxidation resistance protein 1 (87), and B-cell lymphoma 2 (8) as a potential senolytic agents that could extend health span and…”
BackgroundTargeting senescent cells enhances adipogenesis and metabolic function in old age
Xu, M., Palmer, A. K., Ding, H., Weivoda, M. M., Pirtskhalava, T., White, T. A., Sepe, A., Johnson, K. O., Stout, M. B., Giorgadze, N., et al. (2015) · eLife · doi:10.7554/elife.12997 · Cited by 604 · cited 1×
“The concept has been increasingly accepted that by targeting fundamental aging processes, it may be possible to ameliorate a vast array of human diseases associated with old age and is destined to revolutionize the way we think about aging research (6, 28, 29, 43, 50, 84, 85, 88).”
BackgroundToth, P., Tarantini, S., Csiszar, A., & Ungvari, Z. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00581.2016 · Cited by 522 · cited 1×
“Fully within the scope of the geroscience initiative, recent studies have indicated that age-related alterations of the brain microcirculation can initiate the pathogenesis of a spectrum of diseases ranging from vascular cognitive impairment to Alzheimer’s disease (67, 72).”
BackgroundSelf-citationTarantini, S., Tran, C. H. T., Gordon, G. R., Ungvari, Z., & Csiszar, A. (2017) · Experimental Gerontology · doi:10.1016/j.exger.2016.11.004 · Cited by 411 · cited 3×
“Previous studies demonstrate that aging leads to impairment of neurovascular coupling responses due to an age-related impairment of NO bioavailability (59).”
BackgroundSelf-citationAging, Cell Senescence, and Chronic Disease: Emerging Therapeutic Strategies
Tchkonia, T., & Kirkland, J. L. (2018) · JAMA · doi:10.1001/jama.2018.12440 · Cited by 302 · cited 1×
“years, several therapeutic strategies have emerged to target senescent cells for delaying the aging process and preventing the progression of chronic diseases (2, 5, 28, 65).”
BackgroundThe impact of aging on cardiac extracellular matrix
Meschiari, C. A., Ero, O. K., Pan, H., Finkel, T., & Lindsey, M. L. (2017) · GeroScience · doi:10.1007/s11357-017-9959-9 · Cited by 237
Wiley, C. D., Flynn, J. M., Morrissey, C., Lebofsky, R., Shuga, J., Dong, X., Unger, M. A., Vijg, J., Melov, S., & Campisi, J. (2017) · Aging Cell · doi:10.1111/acel.12632 · Cited by 234 · cited 1×
“In recent years, the concept has emerged that presence of senescent cells contributes to the pathogenesis of a wide range of age-related inflammatory diseases (25, 81), such as osteoarthritis (26) and atherosclerosis (9).”
BackgroundRossman, M. J., Kaplon, R. E., Hill, S. D., McNamara, M. N., Santos-Parker, J. R., Pierce, G. L., Seals, D. R., & Donato, A. J. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00416.2017 · Cited by 232 · cited 1×
“It is expected that new studies will lead to a better understanding of the molecular mechanisms underlying the activation of senescence pathways (12, 42, 51).”
BackgroundTucsek, Z., Toth, P., Tarantini, S., Sosnowska, D., Gautam, T., Warrington, J. P., Giles, C. B., Wren, J. D., Koller, A., Ballabh, P., et al. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glu080 · Cited by 191
Self-citationGeroscience and the trans-NIH Geroscience Interest Group, GSIG
Sierra, F., & Kohanski, R. (2017) · GeroScience · doi:10.1007/s11357-016-9954-6 · Cited by 186
Kulkarni, A. S., Brutsaert, E. F., Anghel, V., Zhang, K., Bloomgarden, N., Pollak, M., Mar, J. C., Hawkins, M., Crandall, J. P., & Barzilai, N. (2018) · Aging Cell · doi:10.1111/acel.12723 · Cited by 183 · cited 2×
“The concept has been increasingly accepted that by targeting fundamental aging processes, it may be possible to ameliorate a vast array of human diseases associated with old age and is destined to revolutionize the way we think about aging research (6, 28, 29, 43, 50, 84, 85, 88).”
BackgroundPerrott, K. M., Wiley, C. D., Desprez, P.-Y., & Campisi, J. (2017) · GeroScience · doi:10.1007/s11357-017-9970-1 · Cited by 163 · cited 1×
“This knowledge will enable the development of novel treatments aimed at removing the senescent cellular burden to increase health span by delaying/preventing age-associated pathologies (26, 46).”
BackgroundHodes, R. J., Sierra, F., Austad, S. N., Epel, E., Neigh, G. N., Erlandson, K. M., Schafer, M. J., LeBrasseur, N. K., Wiley, C., Campisi, J., et al. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13299 · Cited by 132
Inhibiting Cellular Senescence: A New Therapeutic Paradigm for Age-Related Osteoporosis
Khosla, S., Farr, J. N., & Kirkland, J. L. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02694 · Cited by 130
Oxidation resistance 1 is a novel senolytic target
Zhang, X., Zhang, S., Liu, X., Wang, Y., Chang, J., Zhang, X., Mackintosh, S. G., Tackett, A. J., He, Y., Lv, D., et al. (2018) · Aging Cell · doi:10.1111/acel.12780 · Cited by 127
Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype
Wiley, C. D., Schaum, N., Alimirah, F., Lopez-Dominguez, J. A., Orjalo, A. V., Scott, G., Desprez, P.-Y., Benz, C., Davalos, A. R., & Campisi, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-20000-4 · Cited by 124 · cited 1×
“Recent studies have identified dasatinib plus quercetin (85), heat shock protein 90 (HSP90) inhibitors (18), fisetin (86), mouse double minute 2 homolog antagonists (82) and agents acting on oxidation resistance protein 1 (87), and B-cell lymphoma 2 (8) as a potential senolytic agents that could extend health span and…”
BackgroundUngvari, Z., Tarantini, S., Hertelendy, P., Valcarcel-Ares, M. N., Fülöp, G. A., Logan, S., Kiss, T., Farkas, E., Csiszar, A., & Yabluchanskiy, A. (2017) · GeroScience · doi:10.1007/s11357-017-9964-z · Cited by 101 · cited 1×
“BBB disruption is another important factor, which plays a key role in increased neuroinflammation in the aging brain (58, 69, 73), likely contributing to the pathogenesis of Alzheimer’s disease and vascular cognitive impairment (56, 57).”
BackgroundSelf-citationTarantini, S., Tucsek, Z., Valcarcel-Ares, M. N., Toth, P., Gautam, T., Giles, C. B., Ballabh, P., Wei, J. Y., Wren, J. D., Ashpole, N. M., et al. (2016) · AGE · doi:10.1007/s11357-016-9931-0 · Cited by 98 · cited 1×
“Extant studies have previously demonstrated that age-related decline in IGF-1 levels contributes significantly to brain (53) and cardiovascular aging (60, 63, 68).”
BackgroundSelf-citationAiello, A. E., Chiu, Y.-L., & Frasca, D. (2017) · GeroScience · doi:10.1007/s11357-017-9983-9 · Cited by 73 · cited 2×
“This is of particular interest to the geroscience community, since over 90% of adults 80 years of age or older exhibit persistent infection with CMV (1, 24, 31, 44, 54), which replicates in the vascular endothelial cells and may contribute to a number of multiorgan age-related microvascular pathologies.”
BackgroundNikolich-Žugich, J., & van Lier, R. A. W. (2017) · GeroScience · doi:10.1007/s11357-017-9984-8 · Cited by 59
Cited by
Immunology of aging: the birth of inflammaging
Fulop, T., Larbi, A., Pawelec, G., Khalil, A., Cohen, A. A., Hirokawa, K., Witkowski, J. M., & Franceschi, C. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08899-6 · Cited by 464
Vaiserman, A., & Krasnienkov, D. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2020.630186 · Cited by 454
“Therefore, development of effective tools for slowing down the aging rate is currently a priority agenda for research organizations and for health policy makers across countries (Yabluchanskiy et al., 2018).”
BackgroundTreating sarcopenic obesity in the era of incretin therapies: perspectives and challenges
Chen, A. S., & Batsis, J. A. (2025) · Diabetes · doi:10.2337/dbi25-0004 · Cited by 32
Brinkley, T. E., Justice, J. N., Basu, S., Bauer, S. R., Loh, K. P., Mukli, P., Ng, T. K. S., Turney, I. C., Ferrucci, L., Cummings, S. R., et al. (2022) · GeroScience · doi:10.1007/s11357-022-00661-w · Cited by 13
Sorlí, J. V., de la Cámara, E., Fernández-Carrión, R., Asensio, E. M., Portolés, O., Ortega-Azorín, C., Pérez-Fidalgo, A., Villamil, L. V., Fitó, M., Barragán, R., et al. (2024) · Nutrients · doi:10.3390/nu17010104 · Cited by 9
“The most prevalent risk factor for a wide range of chronic diseases is aging [1].”
Metadata
- Authors
- Yabluchanskiy, A., Ungvari, Z., Csiszar, A., & Tarantini, S.
- Venue
- Physiology International
- Publisher
- Akademiai Kiado Zrt.
- Published
- 2018-12
- Volume
- 105
- Issue
- 4
- Pages
- 298-308
- ISSN
- 2498-602X (ISSN-L)
- OpenAlex
- W2908460596
- Cited by
- 42
- References
- 34
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.